ÂÜÀòÂÒÂ×

Daniel Geffken is a Founding Managing Director of Danforth Advisors, LLC, a consulting firm providing finance, operations and strategic support to life science companies. He brings more than 30 years of experience in the life science industry to his work with ProMIS, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and several privately held life science companies, in addition to his consulting clients. Daniel has been chief financial officer of Homology, Inc., Transkaryotic Therapies, Inc., Cidara, Inc., Cabaletta Bio, Inc., Apellis, Inc. and Stealth BioTherapeutics, Inc. He has raised more than $1 billion in equity and debt securities for life science companies. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.